DexCom treats about 2.5 million patients, with tons of room for more. The company's Q2 guidance bombshell tanked the stock. Competition from an unexpected source raises long-term concerns worth ...
DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...
DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results